Clinical Trials
1.2k
Trial Phases
5 Phases
Drug Approvals
12
Drug Approvals
Paclitaxel For Injection (Albumin Bound)
- Product Name
- Abraxane
- Approval Number
- 国药准字HJ20130650
- Approval Date
- Dec 20, 2023
Paclitaxel For Injection (Albumin Bound)
- Product Name
- Abraxane
- Approval Number
- H20130650
- Approval Date
- Oct 12, 2018
Clinical Trials
Distribution across different clinical trial phases (1028 trials with phase data)• Click on a phase to view related trials
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 62
- Registration Number
- NCT06988488
- Locations
- 🇨🇦
Local Institution - 0027, Halifax, Nova Scotia, Canada
🇺🇸Local Institution - 0001, Birmingham, Alabama, United States
🇺🇸Local Institution - 0029, New Haven, Connecticut, United States
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4)
- Conditions
- Follicular Lymphoma
- Interventions
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 400
- Registration Number
- NCT06911502
- Locations
- 🇺🇸
Local Institution - 0225, Birmingham, Alabama, United States
🇺🇸Local Institution - 0014, Mobile, Alabama, United States
🇺🇸Alaska Oncology and Hematology, Anchorage, Alaska, United States
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Celgene
- Target Recruit Count
- 120
- Registration Number
- NCT06808984
- Locations
- 🇺🇸
Local Institution - 0046, Homewood, Alabama, United States
🇺🇸University of Alabama - Huntsville Regional Medical Campus, Huntsville, Alabama, United States
🇺🇸NoesisPharma, Phoenix, Arizona, United States
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 200
- Registration Number
- NCT06782490
- Locations
- 🇺🇸
Perseverance Research Center,LLC, Scottsdale, Arizona, United States
🇺🇸Local Institution - 0017, Aurora, Colorado, United States
🇺🇸Local Institution - 0068, Naples, Florida, United States
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2025-01-08
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Celgene
- Target Recruit Count
- 960
- Registration Number
- NCT06764485
- Locations
- 🇺🇸
Colorado Clinical Research, Lakewood, Colorado, United States
🇺🇸Thomas Jefferson University, Kennedy Health Alliance, Sewell, New Jersey, United States
🇺🇸Thomas Jefferson University - Clinical Research Institute, Philadelphia, Pennsylvania, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 96
- Next
News
FAERS Analysis Reveals Lower Infection Risk with Ide-cel Compared to Other BCMA-Targeted Therapies in Multiple Myeloma
A retrospective analysis of FDA Adverse Event Reporting System (FAERS) data from 2021-2024 found that idecabtagene vicleucel (ide-cel) was associated with significantly lower infection rates compared to other BCMA-directed therapies in multiple myeloma patients.
Major Pharmaceutical Companies Face Surge in Generic Drug Patent Challenges in Early 2025
Major pharmaceutical companies including AstraZeneca, Novartis, and Astellas are defending patents for blockbuster drugs like Lynparza, Entresto, and Xtandi against generic manufacturers in early 2025.
Major Pharma M&A Surge and Landmark Antitrust Rulings Shape 2025 Life Sciences Landscape
The first half of 2025 witnessed unprecedented M&A activity with major deals including Merck's $3.9 billion SpringWorks acquisition, Sanofi's $9.5 billion Blueprint Medicines purchase, and Johnson & Johnson's $14.6 billion Intra-Cellular Therapies acquisition.
Cigna Sues Bristol Myers Squibb Over Alleged Monopoly Practices for Cancer Drug Pomalyst
Cigna filed a federal lawsuit against Bristol Myers Squibb, alleging the company used anti-competitive strategies to maintain a monopoly on Pomalyst, a multiple myeloma treatment that generated $2.7 billion in U.S. sales last year.
Priothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Lead Phase 3 Trial of Mocravimod for Acute Myeloid Leukemia
Priothera has appointed Dr. Jens Hasskarl as Chief Medical Officer to oversee the global Phase 3 MO-TRANS study of mocravimod in acute myeloid leukemia patients.
Evotec and Bristol Myers Squibb Achieve Major Milestone in Molecular Glue Degrader Collaboration, Triggering $75M Payment
Evotec SE announced significant progress in its strategic protein degradation collaboration with Bristol Myers Squibb, triggering performance-based payments totaling $75 million.
B-Cell Lymphoma Pipeline Expands with 300+ Therapies in Development for 2025
DelveInsight's latest report reveals a robust B-cell lymphoma pipeline with over 295 companies developing 300+ therapies, highlighting significant industry investment in this area.
AstraZeneca Acquires European Cell Therapy Biotech in Deal Worth Up to $1 Billion
AstraZeneca has expanded its cell therapy portfolio by acquiring a European biotech company in a deal valued at up to $1 billion, strengthening its position in the advanced therapeutics market.
Bayer and CRISPR Therapeutics Form $300 Million Joint Venture to Advance Gene-Editing Therapies
Bayer is investing $300 million over five years in a new joint venture with CRISPR Therapeutics, plus $35 million for a minority stake in the gene-editing pioneer.
Novel Chemo-Immunotherapy Approach Shows Promise for Advanced HPV-Negative Head and Neck Cancer
A Phase 2 clinical trial at UChicago Medicine demonstrated that combining nivolumab immunotherapy with chemotherapy led to tumor shrinkage in 53% of advanced HPV-negative head and neck cancer patients.